Market Overview

Bank of America Merrill Lynch Reiterates Buy Rating, $49 PT on CVS Caremark Corporation

Share:
Related CVS
PBM Space Gets Cozier With Anthem's New In-House Service, Amazon's Rumored Entrance
Jim Cramer Gives His Opinion On Steel Dynamics And CVS Health
Inverness Counsel Inc Buys CVS Health Corp, JPMorgan Chase, Corning Inc, Sells Dover Corp, ... (GuruFocus)

In a report published Friday, Bank of America Merrill Lynch reiterated its Buy rating and $49.00 price target on CVS Caremark Corporation (NYSE: CVS).

BofA Merrill Lynch noted, “According to media reports, CVS will buy an 80% stake in Brazilian retail pharmacy chain Onofre for $313 million, plus assumed debt. The deal adds 44 stores (the eighth-largest chain in Brazil) in a high-growth region with rapidly expanding health care coverage. However, we maintain our 2013 EPS estimate ($3.57) at this time, on the relatively small investment size and what we expect are few operating synergies.”

CVS Caremark Corporation closed on Thursday at $46.71.

Latest Ratings for CVS

DateFirmActionFromTo
Sep 2017RBC CapitalInitiates Coverage OnOutperform
Sep 2017JefferiesMaintainsHold
Aug 2017Loop CapitalInitiates Coverage OnHold

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Reiteration Analyst Ratings

 

Related Articles (CVS)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...